ESR1 and Alzheimer disease: In this regard, the use of Raloxifene, a selective estrogen receptor modulator, which is known for its protective effects in liver and bone tissue without increasing estrogen-dependent tumor risks, was investigated in women since the higher prevalence of AD patients.